Elevance Health, Inc. $ELV Shares Sold by Bokf Na

Key Points

• Bokf Na cut its Elevance Health stake by 61.5% in the fourth quarter, selling 4,704 shares and leaving it with 2,941 shares worth about $1.03 million.
• Elevance Health posted stronger-than-expected quarterly results, reporting EPS of $12.58 versus estimates of $10.74 and revenue of $49.49 billion, while also guiding FY 2026 EPS to 19.850.
• Analysts remain cautiously positive: the stock has a consensus rating of “Moderate Buy” with a $384.58 average price target, though RBC recently downgraded it to sector perform.

Bokf Na decreased its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 61.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,941 shares of the company's stock after selling 4,704 shares during the quarter. Bokf Na's holdings in Elevance Health were worth $1,031,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ELV. Artisan Partners Limited Partnership increased its stake in Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company's stock worth $1,478,857,000 after buying an additional 901,626 shares during the period. First Eagle Investment Management LLC increased its stake in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company's stock worth $1,292,029,000 after buying an additional 798,457 shares during the period. Brave Warrior Advisors LLC increased its stake in Elevance Health by 65.3% during the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company's stock worth $592,603,000 after buying an additional 724,349 shares during the period. Baupost Group LLC MA increased its stake in Elevance Health by 114.1% during the 3rd quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company's stock worth $426,195,000 after buying an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC increased its stake in Elevance Health by 44.2% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company's stock worth $660,935,000 after buying an additional 627,038 shares during the period. Institutional investors and hedge funds own 89.24% of the company's stock.

Elevance Health Trading Up 1.3%

Elevance Health stock opened at $377.66 on Friday. The firm has a 50 day simple moving average of $312.92 and a 200-day simple moving average of $332.13. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The stock has a market capitalization of $82.01 billion, a PE ratio of 16.06, a price-to-earnings-growth ratio of 2.12 and a beta of 0.66. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $424.24.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to analysts' expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business's revenue was up 1.5% on a year-over-year basis. During the same period last year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities research analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health's dividend payout ratio is 29.26%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada downgraded shares of Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 target price for the company. in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. boosted their target price on shares of Elevance Health from $397.00 to $411.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 28th. UBS Group set a $400.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Truist Financial dropped their target price on shares of Elevance Health from $390.00 to $375.00 and set a "buy" rating for the company in a research report on Monday, April 13th. Finally, Weiss Ratings raised shares of Elevance Health from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Friday, April 24th. Thirteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $384.58.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance beat first-quarter expectations and raised EPS guidance, which is helping support investor confidence in the company’s near-term outlook. A Look At Elevance Health (ELV) Valuation After Q1 Beat And Raised EPS Guidance
• Positive Sentiment: Zacks Research lifted FY2026 EPS estimates to $26.79 from $25.53, matching the consensus estimate and signaling stronger expected earnings this year.
• Positive Sentiment: Zacks also raised FY2027 EPS estimates to $28.51 from $28.40, and increased its Q2 2027 forecast to $7.23 from $7.20, suggesting analysts still see healthy longer-term profitability.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.